Profile data is unavailable for this security.
About the company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
- Revenue in -- (TTM)--
- Net income in --
- Incorporated2013
- Employees--
- LocationAbivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
- Phone+33 153830963
- Fax+33 494279261
- Websitehttps://www.abivax.com/
More ▼
27.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 31 Dec 2025 | 4.42m | 5.64% |
| Darwin Global Management Ltd.as of 30 Sep 2025 | 3.16m | 4.03% |
| Point72 Asset Management LPas of 30 Sep 2025 | 2.93m | 3.73% |
| Cormorant Asset Management LPas of 30 Sep 2025 | 1.95m | 2.49% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.73m | 2.21% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 1.56m | 1.99% |
| Caligan Partners LPas of 30 Sep 2025 | 1.45m | 1.85% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 1.43m | 1.82% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 1.35m | 1.72% |
| Octagon Capital Advisors LPas of 30 Sep 2025 | 1.33m | 1.69% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
